

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

宜昌東陽光長江藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 01558)

**POLL RESULTS OF
2023 THIRD EXTRAORDINARY GENERAL MEETING
HELD ON 27 DECEMBER 2023**

References are made to the notice of 2023 third extraordinary general meeting (the “**EGM**”) and the circular (the “**Circular**”) of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the “**Company**”) dated 1 December 2023, and the supplemental notice of the EGM and the supplemental circular of the Company dated 8 December 2023 (the “**Supplemental Circular**”). Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular and the Supplemental Circular.

POLL RESULTS OF THE EGM

The EGM was convened and held at Conference Room, 4/F, Administration Building, Dongyangguang Scientific Park, No. 368 Zhen An Zhong Road, Chang’an County, Dongguan, Guangdong Province, the PRC on Wednesday, 27 December 2023. The EGM was convened lawfully and validly in accordance with the Company Law and other relevant laws and regulations of the PRC, the Listing Rules and the Articles of Association.

As at the date of the EGM, the total number of issued Shares of the Company was 879,967,700 Shares (comprising a total of 226,200,000 issued Domestic Shares and a total of 653,767,700 issued H Shares), all of which entitled the holders to attend and vote for or against or abstain from voting on the resolutions proposed at the EGM.

Shareholders attending the EGM, either in person or by proxy, held an aggregate of 169,899,786 Shares with voting rights, representing approximately 19.307503% of the total number of the issued Shares.

Sunshine Lake Pharma has the right to control the exercise of approximately 51.41% of voting rights in the Company, and is therefore a controlling Shareholder and a connected person of the Company. Shenzhen HEC Industrial is the holding company of the Sunshine Lake Pharma. Therefore, as an associate of Sunshine Lake Pharma, Shenzhen HEC Industrial constitutes a connected person of the Company by virtue of being the holding

company of the controlling Shareholder of the Company pursuant to Chapter 14A of the Listing Rules. Shenzhen HEC Industrial and its associates, such as Sunshine Lake Pharma and HEC (Hong Kong) Sales Co., Limited, were therefore deemed to have a material interest in (i) the Framework Agreement and the transactions contemplated thereunder (including the Authorisation and the proposed annual caps for the R&D pipeline cooperation projects) entered into between the Company and Sunshine Lake Pharma and (ii) the proposed revision of annual caps of each of the Energy Purchase Framework Agreement, the APIs Purchase Agreement, the Packaging and Production Materials Purchase Framework Agreement and the Entrusted Processing Framework Agreement entered into between the Company and Shenzhen HEC Industrial, and were required to abstain from voting on resolutions numbered 1 to 6 proposed at the EGM. Save as disclosed above, no Shareholder was required by the Listing Rules to abstain from voting on any of the resolutions proposed at the EGM.

There was no Share entitling its holder to attend the EGM and abstain from voting in favour of any of the proposed resolutions under Rule 13.40 of the Listing Rules. Save as disclosed above, no Shareholder has stated the intention in the Circular and the Supplemental Circular to vote against or to abstain from voting on any of the proposed resolutions.

All the proposed resolutions were voted by way of poll. Computershare Hong Kong Investor Services Limited, the H share registrar of the Company, acted as the scrutineer for vote-taking and vote-tabulation at the EGM. Two representatives from the Shareholders and one supervisor of the Company also acted as the scrutineers for the vote-taking and vote-tabulation.

All Directors attended the EGM.

Poll Results of the EGM

The poll results of the EGM are as follows:

ORDINARY RESOLUTIONS		NUMBER OF VOTES AND PERCENTAGE OF TOTAL NUMBER OF VOTES (%)					
		FOR		AGAINST		ABSTAIN	
		NUMBER OF VOTES	PERCENTAGE OF TOTAL NUMBER OF VOTES (%)	NUMBER OF VOTES	PERCENTAGE OF TOTAL NUMBER OF VOTES (%)	NUMBER OF VOTES	PERCENTAGE OF TOTAL NUMBER OF VOTES (%)
1.	(a) the execution of the Framework Agreement (as defined in the Circular of the Company dated 1 December 2023) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the Framework Agreement and the proposed annual caps for the R&D cooperation expenses as set out in the Circular be and are hereby approved.	122,519,586	72.112855	46,453,400	27.341647	926,800	0.545498

ORDINARY RESOLUTIONS		NUMBER OF VOTES AND PERCENTAGE OF TOTAL NUMBER OF VOTES (%)					
		FOR		AGAINST		ABSTAIN	
		NUMBER OF VOTES	PERCENTAGE OF TOTAL NUMBER OF VOTES (%)	NUMBER OF VOTES	PERCENTAGE OF TOTAL NUMBER OF VOTES (%)	NUMBER OF VOTES	PERCENTAGE OF TOTAL NUMBER OF VOTES (%)
2.	The board of directors of the Company be and are hereby authorised to do all such acts and things and execute all documents as he/she considers necessary, desirable or expedient for the purpose of, or in connection with, the Review of the List of R&D cooperation projects (as defined in the Circular of the Company dated 1 December 2023) or any matter related thereto.	122,519,586	72.112855	46,453,400	27.341647	926,800	0.545498
3.	To approve the Revised Annual Cap for the Energy Purchase Framework Agreement and the transactions contemplated thereunder.	122,519,586	72.459844	45,639,800	26.992033	926,800	0.548123
4.	To approve the Revised Annual Caps for the APIs Purchase Agreement and the transactions contemplated thereunder.	122,519,586	72.459844	45,639,800	26.992033	926,800	0.548123
5.	To approve the Revised Annual Caps for the Packaging and Production Materials Purchase Framework Agreement and the transactions contemplated thereunder.	122,519,586	72.459844	45,639,800	26.992033	926,800	0.548123
6.	To approve the Revised Annual Cap for the Entrusted Processing Framework Agreement and the transactions contemplated thereunder.	122,519,586	72.459844	45,639,800	26.992033	926,800	0.548123

As more than half of the votes from the Shareholders (including their proxies) attending the EGM were cast in favour of the resolutions numbered 1 to 6, these resolutions were duly passed as ordinary resolutions.

On behalf of the Board
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
TANG Xinfa
Chairman

Hubei, the PRC
27 December 2023

As at the date of this announcement, the Board consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. LI Shuang and Mr. CHEN Hao as executive Directors; Mr. TANG Xinfa as a non-executive Director; and Mr. TANG Jianxin, Ms. XIANG Ling and Mr. LI Xuechen as independent non-executive Directors.